Taxoids

"Taxoids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.

Descriptor ID	D043823
MeSH Number(s)	D02.455.426.392.368.242.888 D02.455.849.291.850
Concept/Terms	Taxoids Taxoids Taxanes Taxanes

Below are MeSH descriptors whose meaning is more general than "Taxoids".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Cyclic [D02.455.426]
Hydrocarbons, Alicyclic [D02.455.426.392]
Cycloparaffins [D02.455.426.392.368]
Cyclodecanes [D02.455.426.392.368.242]
Taxoids [D02.455.426.392.368.242.888]
Terpenes [D02.455.849]
Diterpenes [D02.455.849.291]
Taxoids [D02.455.849.291.850]

Below are MeSH descriptors whose meaning is related to "Taxoids".

Below are MeSH descriptors whose meaning is more specific than "Taxoids".

Taxoids
Paclitaxel

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Taxoids" by people in this website by year, and whether "Taxoids" was a major or minor topic of these publications.

Bar chart showing 81 publications over 23 distinct years, with a maximum of 7 publications in 2003 and 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	0	1
1998	0	1	1
2000	1	1	2
2001	1	0	1
2002	5	0	5
2003	4	3	7
2004	2	0	2
2005	2	4	6
2006	1	4	5
2007	0	1	1
2008	1	4	5
2009	2	2	4
2010	2	2	4
2011	1	5	6
2012	0	3	3
2013	0	1	1
2014	1	2	3
2015	4	3	7
2016	3	3	6
2017	1	1	2
2018	0	2	2
2020	1	2	3
2024	0	4	4

Below are the most recent publications written about "Taxoids" by people in Profiles.

La Cerda J, Thorley J, Sieber P, Cookson MS, Flanders SC, Gatoulis SC, Shore ND. Plain language review: the safety of relugolix combination therapy for advanced prostate cancer. Future Oncol. 2025 Jan; 21(1):51-62.

View in: PubMed
Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Fl?chon A, Wei XX, Mahammedi H, Roubaud G, ?tudentov? H, Nagarajah J, Mellado B, Montesa-Pino ?, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024 09 28; 404(10459):1227-1239.

View in: PubMed
Morgans AK, Grossman JP, Paracha N, Ladino D, Tyas E, Rodriguez-Santamaria F, Shore N. Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS. J Manag Care Spec Pharm. 2024 Sep; 30(9):991-1000.

View in: PubMed
Vaishampayan UN, Keessen M, Dreicer R, Heath EI, Buchler T, ?rkosy PF, Cs?szi T, Wiechno P, Kopyltsov E, Orlov SV, Plekhanov A, Smagina M, Varlamov S, Shore ND. A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer. Eur J Cancer. 2024 05; 202:114007.

View in: PubMed
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, ?zg?roglu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 12 10; 383(24):2345-2357.

View in: PubMed
Chung IY, Lee JW, Moon HG, Shin KH, Han W, Son BH, Ahn SH, Noh DY. Effect of standard low-dose anthracycline chemotherapy on late congestive heart failure in breast cancer survivors aged between 50 and 59?at diagnosis: A nationwide study. Breast. 2020 Oct; 53:125-129.

View in: PubMed
Lin J, Den RB, Greenspan J, Showalter TN, Hoffman-Censits JH, Lallas CD, Trabulsi EJ, Gomella LG, Hurwitz MD, Leiby B, Dicker AP, Kelly WK. Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020 04 01; 106(5):939-947.

View in: PubMed
Jain S, Shah AN, Santa-Maria CA, Siziopikou K, Rademaker A, Helenowski I, Cristofanilli M, Gradishar WJ. Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. Breast Cancer Res Treat. 2018 Sep; 171(2):371-381.

View in: PubMed
Parker C, Heidenreich A, Nilsson S, Shore N. Current approaches to incorporation of radium-223 in clinical practice. Prostate Cancer Prostatic Dis. 2018 04; 21(1):37-47.

View in: PubMed
Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CAF, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. Cancer. 2017 Jul 01; 123(13):2489-2496.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement